Table 3.
Adverse events of interest.
| Adverse Event | All Grades | Grade ≥3 | ||||||
|---|---|---|---|---|---|---|---|---|
| I 2 | RR (95% CI) | p | Incidence of EG | I 2 | RR (95% CI) | p | Incidence of EG | |
| Fever | 73% | 3.87 (2.15, 6.69) |
<0.00001 * | 48.90% | 0% | 3.07 (0.62, 15.10) |
0.17 | 1.825% |
| Neutropenia | 67% | 1.66 (1.21, 2.29) |
0.002 * | 63.01% | 50% | 1.36 (1.03, 1.80) |
0.03 * | 40.36% |
| Febrile neutropenia | 66% | 1.76 (0.66,4.69) |
0.25 | 25.18% | 3% | 1.19 (0.77, 1.84) |
0.44 | 15.52% |
| Leukopenia | 36% | 1.21 (0.96, 1.51) |
0.11 | 71.23% | 90% | 1.84 (0.23, 14.36) |
0.56 | 26.61% |
| Diarrhea | 17% | 1.56 (1.26, 1.95) |
<0.0001 * | 28.78% | 13% | 1.12 (0.56, 2.22) |
0.75 | 2.178% |
| Nausea | 35% | 1.49 (1.28, 1.74) |
<0.00001 * | 45.24% | 0% | 1.05 (0.48, 2.29) |
0.89 | 1.754% |
| Vomiting | 36% | 1.65 (1.27, 2.14) |
0.0002 * | 27.84% | 5% | 0.68 (0.30, 1.52) |
0.35 | 1.983% |
| Chills | 32% | 7.04 (4.64, 10.66) |
<0.00001 * | 45.84% | NA | 0.92 (0.04, 21.85) |
0.96 | 0.1825% |
| Fatigue | 85% | 1.22 (0.95, 1.57) |
0.12 | 55.35% | 0% | 1.24 (0.83, 1.85) |
0.29 | 6.836% |
| Flu-like symptoms | 60% | 4.13 (2.15, 7.94) |
<0.0001 * | 31.29% | 0% | 4.41 (0.82, 23.81) |
0.08 | 1.23% |
| Decreased appetite/anorexi-a | 25% | 1.23 (0.98, 1.56) |
0.08 | 25.91% | 51% | 0.55 (0.17, 1.76) |
0.32 | 0.6048% |
| Arthralgia | 13% | 1.51 (1.09, 2.12) |
0.01 * | 19.01% | 0% | 0.94 (0.19, 4.67) |
0.94 | 0.6073% |
| Myalgia | 47% | 1.97 (1.32, 2.96) |
0.001 * | 18.42% | NA | 1.31 (0.05, 31.96) |
0.87 | 0.2208% |
| Pain in extremity | 0% | 1.50 (1.06, 2.11) |
0.02 * | 20.98% | 0% | 1.57 (0.40, 6.21) |
0.52 | 1.897% |
| Headache | 0% | 1.90 (1.42, 2.53) |
<0.0001 * | 24.11% | 0% | 1.86 (0.47, 7.34) |
0.38 | 1.095% |
| Cough | 17% | 0.85 (0.67, 1.07) |
0.17 | 21.66% | NA | 0.32 (0.01, 7.85) |
0.49 | 0 |
| Cellulitis | NA | 3.70 (0.87, 15.76) |
0.08 | 5.822% | NA | 2.64 (0.31, 22.18) |
0.37 | 2.055% |
| Thrombocytope-nia | 0% | 2.74 (1.65, 4.57) |
0.0001 * | 54.79% | 0% | 1.23 (0.58, 2.61) |
0.59 | 10.09% |
*, statistically significant value; 95% CI, 95% confidence interval; RR, risk ratio; NA, not available; I2, index of heterogeneity; EG, experimental group.